Actively Recruiting

Phase 3
Age: 6Years - 11Years
All Genders
ID06807268

A 16-Week, Randomized, Double-Blind, Placebo-Controlled Study of Abrocitinib in Children 6 to Less Than 12 Years With Moderate-to-Severe Atopic Dermatitis

Led by Pfizer · Updated on 2026-05-06

150

Participants Needed

41

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the effects and safety of abrocitinib, a test medicine, in children aged 6 to less than 12 years who have moderate-to-severe eczema. The study is designed to compare abrocitinib with a placebo, a look-alike medicine without active ingredients, to better understand how well abrocitinib works for this condition. The research will last about 24 weeks, including 16 weeks of treatment. Participants will be randomly assigned to receive either abrocitinib or placebo as a liquid oral suspension daily for 16 weeks. The study uses questionnaires and an electronic diary on a device similar to a cellphone to track eczema symptoms and remind participants to take their medicine. Children will also wear a wrist device resembling a watch to detect scratching caused by eczema. Health will be monitored with lab tests, physical exams, and vital signs throughout the study. During the study, participants will visit the clinic for assessments and receive calls from the study doctor or nurse to check on their condition. Questionnaires will help measure eczema severity and itchiness, while the wrist device tracks scratching behavior. The main outcomes measured include improvement in skin condition and itch severity by week 12. Safety and health monitoring will continue through the study, ensuring detailed observation of treatment effects and participant well-being.

CONDITIONS

Brief Title

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

Who Can Participate

Age: 6Years - 11Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Children aged 6 to less than 12 years at the time of consent
  • Documented diagnosis of chronic atopic dermatitis for at least 1 year
  • Moderate-to-severe atopic dermatitis at baseline (BSA ≥10%, vIGA ≥3, EASI ≥16, WI-NRS ≥4)
  • History of inadequate response to topical medical therapy for atopic dermatitis within 6 months
  • Body weight of at least 15 kilograms
  • Male participants have no contraception requirements as per study appendix
Not Eligible

You will not qualify if you...

  • Any medical or psychiatric condition that increases risk or is judged inappropriate by the investigator
  • SDQ total score ≥17 without clearance by a pediatric mental health professional
  • Skin infections requiring systemic treatment within 2 weeks or superficial infections within 1 week prior to baseline
  • History of systemic infection requiring hospitalization or significant infections within 1 month prior to baseline
  • History of disseminated herpes zoster or herpes simplex infections
  • Infection with HIV, hepatitis B or C
  • Active or inadequately treated tuberculosis
  • Skin conditions like psoriasis, seborrheic dermatitis, or lupus interfering with evaluation
  • History of skeletal dysplasia or retinal detachment
  • History or conditions related to thrombocytopenia, coagulopathy, or platelet dysfunction
  • History of leukemia, lymphoma, sarcoma, or other malignancies
  • Immunodeficiency disorders or first-degree relatives with hereditary immunodeficiency
  • Prior treatment with systemic JAK inhibitors for atopic dermatitis
  • Live attenuated vaccinations within 6 weeks prior to baseline or planned during treatment
  • Use of strong CYP2C19 and CYP2C9 enzyme inhibitors or inducers, P-gp substrates with narrow therapeutic index
  • Prior investigational drug use within 30 days or 5 half-lives before baseline

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 16 weeks

Participants receive Abrocitinib or placebo as a liquid oral suspension and complete questionnaires about their eczema using an electronic diary. They also wear a wrist device to monitor scratching and have laboratory tests, physical exams, and vital signs monitored to assess health.

Clinic visits and phone calls during the study as scheduled by the study staff

Trial Site Locations

Total: 41 locations

1

Cahaba Dermatology & Skin Health Center, LLC

Birmingham, Alabama, United States, 35244

Actively Recruiting

2

Arkansas Research Trials

North Little Rock, Arkansas, United States, 72117

Actively Recruiting

3

Investigational Drug Service - Rady Childrens Hospital-San Diego

San Diego, California, United States, 92123

Actively Recruiting

4

University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm

San Diego, California, United States, 92123

Actively Recruiting

5

Solutions Through Advanced Research

Jacksonville, Florida, United States, 32256

Actively Recruiting

6

Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, United States, 46250

Actively Recruiting

7

Saint Louis University - Department of Dermatology

St Louis, Missouri, United States, 63104

Actively Recruiting

8

Medical University of South Carolina

Charleston, South Carolina, United States, 29425

Actively Recruiting

9

Tribe Clinical Research, LLC

Greenville, South Carolina, United States, 29607

Actively Recruiting

10

Texas Dermatology and Laser Specialists

San Antonio, Texas, United States, 78235

Actively Recruiting

11

Beijing Children's hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100045

Actively Recruiting

12

Shenzhen Children's Hospital

Shenzhen, Guangdong, China, 518026

Actively Recruiting

13

Hunan Children's Hospital

Changsha, Hunan, China, 410007

Actively Recruiting

14

Dermatology Hospital of Jiangxi Province

Nanchang, Jiangxi, China, 330000

Actively Recruiting

15

Shanghai Children's Hospital

Shanghai, Shanghai Municipality, China, 200040

Actively Recruiting

16

Hangzhou Third People's Hospital

Hangzhou, Zhejiang, China, 310009

Actively Recruiting

17

Shanghai Children's Hospital

Shanghai, China, 200062

Actively Recruiting

18

Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine

Shanghai, China, 200092

Actively Recruiting

19

Universitätsklinikum Münster

Münster, North Rhine-Westphalia, Germany, 48149

Not Yet Recruiting

20

Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden

Dresden, Saxony, Germany, 01307

Actively Recruiting

21

Pécsi Tudományegyetem Klinikai Központ

Pécs, Baranya, Hungary, 7632

Actively Recruiting

22

Trial Pharma Kft.

Békéscsaba, Bekes County, Hungary, 5600

Not Yet Recruiting

23

Clinexpert Kft.

Budapest, Pest County, Hungary, 1033

Actively Recruiting

24

University of Pecs

Pécs, Hungary, 7622

Actively Recruiting

25

Queen's square Medical Facilities Queen's square Dermatology and Allergology

Yokohama, Kanagawa, Japan, 220-6208

Actively Recruiting

26

Dermatology and Ophthalmology Kume Clinic

Sakai, Osaka, Japan, 593-8324

Actively Recruiting

27

Sasamoto Children's Clinic

Setagaya-ku, Tokyo, Japan, 157-0066

Actively Recruiting

28

Fukuoka National Hospital

Fukuoka, Japan, 811-1394

Actively Recruiting

29

Saruta Dermatology Clinic

Fukuoka, Japan, 819-0042

Actively Recruiting

30

Eukarya Pharmasite S.C.

Monterrey, Nuevo León, Mexico, 64718

Not Yet Recruiting

31

Arke SMO S.A. de C.V.

Veracruz, Veracruz, Mexico, 91900

Not Yet Recruiting

32

Servicios Hospitalarios de México S.A. de C.V. (Hospital Angeles Chihuahua)

Chihuahua City, Mexico, 31238

Not Yet Recruiting

33

LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska

Lublin, Lublin Voivodeship, Poland, 20-573

Actively Recruiting

34

Centrum Medyczne Evimed

Warsaw, Masovian Voivodeship, Poland, 02-625

Actively Recruiting

35

DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska

Chorzów, Silesian Voivodeship, Poland, 41-500

Actively Recruiting

36

Centrum Medyczne Angelius Provita

Katowice, Silesian Voivodeship, Poland, 40-611

Actively Recruiting

37

Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak

Lodz, Łódź Voivodeship, Poland, 90-436

Actively Recruiting

38

Dermedic Jacek Zdybski

Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Poland, 27-400

Actively Recruiting

39

CHUS - Hospital Clinico Universitario

Santiago de Compostela, A Coruña [LA Coruña], Spain, 15706

Actively Recruiting

40

Hospital General de Granollers

Granollers, Barcelona [barcelona], Spain, 08402

Actively Recruiting

41

Hospital Universitario Miguel Servet

Zaragoza, Spain, 50009

Actively Recruiting

Loading map...

Research Team

P

Pfizer CT.gov Call Center

N

Nancy A Sherman, BA

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Double-Blind, Randomized, Vehicle-Controlled Study to Asse...

Eczema Atopic Dermatitis

Actively Recruiting

1 location

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-c...

Atopic Dermatitis

Actively Recruiting

85 locations

A European, Multicenter, Prospective Observational Study to ...

Atopic Dermatitis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here